Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Outcomes of Hodgkin lymphoma patients who receive a second ASCT

Anna Sureda • 3 Dec 2018
ASH 2018
Hodgkin Lymphoma Lymphoma

Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the latest EBMT Lymphoma Working Party registry study. This evaluated the outcome of relapsed/refractory Hodgkin lymphoma patients who received a second autologous stem cell transplantation (ASCT2). Dr Sureda highlights the key messages from this study; the time between transplants is the most important predictive factor for long-term outcomes.

More from Anna Sureda

1:54
Looking forward to the 50th Annual Meeting of the EBMT
Anna Sureda • 7 Mar 2024
3:32
The risk of secondary malignancies following CAR T-cell therapy: current evidence
Anna Sureda • 7 Mar 2024
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:16
The success of the EBMT-EHA 6th European CAR T-cell Meeting
Anna Sureda • 7 Mar 2024

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals